Savara Inc. (SVRA), a biopharmaceutical company, Thursday announced that it has introduced the aPAP ClearPath Dried Blood Spot Test in the U.S.
This new test builds on its prior serum-based assay, offering a simpler way to diagnose autoimmune pulmonary alveolar proteinosis or aPAP, using just a finger-prick blood sample.
Autoimmune PAP is a rare lung disease caused by antibodies that disrupt surfactant clearance, leading to respiratory issues. Left untreated, it can result in severe complications such as lung fibrosis and transplant.
The DBS test has shown a strong correlation between GM-CSF autoantibody levels in dried and traditional serum samples, achieving 100 percent analytical sensitivity and specificity. Developed in partnership with TrilliumBiO, a CLIA-certified lab, the test is noninvasive and available at no cost.
SVRA is currently trading at $2.67 up 2.88 percent or $0.07 on the Nasdaq.
For comments and feedback: editorial@rttnews.com